WO2010045788A1 - 盐酸多奈哌齐口腔崩解片及其制备方法 - Google Patents
盐酸多奈哌齐口腔崩解片及其制备方法 Download PDFInfo
- Publication number
- WO2010045788A1 WO2010045788A1 PCT/CN2009/001179 CN2009001179W WO2010045788A1 WO 2010045788 A1 WO2010045788 A1 WO 2010045788A1 CN 2009001179 W CN2009001179 W CN 2009001179W WO 2010045788 A1 WO2010045788 A1 WO 2010045788A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- donepezil hydrochloride
- orally disintegrating
- cellulose
- disintegrating tablet
- sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to a donepezil hydrochloride orally disintegrating tablet and a preparation method thereof, and, in particular, to an orally disintegrating tablet containing donepezil hydrochloride and a preparation method thereof.
- the donepezil hydrochloride orally disintegrating tablet can be used for the treatment of Alzheimer's disease. Background technique
- Donepezil Hydrochloride is a second-generation cholinesterase inhibitor (AChEI) for the treatment of Alzheimer's disease. It is highly selective for neuronal acetylcholinesterase, which increases the acetylcholine content in the brain by inhibiting acetylcholinesterase. Increased acetylcholine content in the synapse directly involved in neurotransmission, resulting in a therapeutic effect, can improve learning disabilities. There is almost no inhibition of acetylcholinesterase in the heart and intestine, so the selectivity is strong, the action time is long, and the side effects are small. No liver toxicity and other characteristics. It is an ideal drug for the treatment of premature dementia.
- AChEI second-generation cholinesterase inhibitor
- An orally disintegrating tablet is a tablet that can rapidly disintegrate, disperse or dissolve in saliva in the oral cavity.
- the patient does not need water or a small amount of water, and does not need to chew.
- the drug is placed in the oral cavity, and the saliva quickly dissolves or disintegrates. After that, the patient's autonomic and involuntary swallowing action enters the digestive system and then takes effect. It is convenient for some people to take medicines, such as the elderly, children, dysphagia or patients in special circumstances.
- This dosage form can provide a new method of taking compared with ordinary tablets.
- flavoring is one of the key items in prescription screening when developing orally disintegrating tablets.
- sweeteners or flavors are generally used for flavoring.
- the complex formed by the drug-ion exchange resin is a more successful flavoring technique, which is obtained by spray drying a drug and an ion exchange resin under a certain pH condition.
- the drug is not easily replaced by the exchange resin, but in the gastric acid, the drug is separated from the exchange resin by the exchange of hydrogen ions, thereby better solving the problem of bitterness of the drug.
- the application of the powder coating technology can better solve the bad odor of the drug. Therefore, the scientific and rational design of flavoring technology is particularly important in the development of oral disintegration tablets.
- the techniques for preparing orally disintegrating tablets at home and abroad include: freeze-drying tableting technology and General powder granule tableting technology widely used in China. From the standard of the prepared orally disintegrating tablets, the orally disintegrating tablets obtained by freeze-dried tableting are loose in texture, and the disintegration time is generally within 15 seconds, but the technique is a patented technique and is difficult to be widely used. Oral disintegrating tablets prepared by wet granulation tableting technology, in order to obtain the effect of rapid disintegration, a large amount of disintegrant is usually added in the prescription (generally using internal and external addition), and the disintegrating tablet prepared by the preparation method is The disintegration time limit can be met.
- the tablet is hard, the disintegration time is generally longer, and the mouthfeel is poor.
- the disintegrant adheres to the oral cavity after absorbing water, which inevitably requires Drink water to swallow the drug. This loses the greatest advantage of the disintegrant, and may also result in poor compliance with the medication due to the bitterness of the drug.
- L-HPC Low-substituted hydroxypropylcellulose
- L-HPC-1 1 is medium degree of substitution, the largest particle size, mainly used to prevent tablet cracking and direct tableting disintegrant;
- L-HPC-21 is mainly used as a binder for wet granulation tablets and Disintegrant;
- L-HPC-31 is a grade with a small particle size, which is easier to pass through a mesh screen and is mainly used for extrusion granulation.
- the orally disintegrating tablet has the disadvantages of small tablet hardness and high friability, it is particularly important to select a suitable disintegrant and excipient in the preparation process.
- the inventors prepared D-mannitol and cross-linked polyvinylpyrrolidone (PVPP) into a composite disintegrator, and prepared an orally disintegrating tablet by direct compression molding, and as a result, had good disintegration characteristics, but the tablet had a high hardness.
- the milled D-mannitol is smaller than ordinary mannitol particles, and the circularity and surface area are increased, so that the inlaid dots per unit area are increased, and the hardness of the tablet is increased.
- the Zydis method is different from the ordinary freeze-drying method, such as the powder freeze-drying process, mainly in which the main drug and the auxiliary material are quantitatively packed in a certain mold, and lyophilized to remove water to obtain a solid preparation with high porosity.
- the Orasolv method also adopts gelatin and microcrystalline cellulose to encapsulate the main drug into small particles to mask the taste, adding a larger amount of mannitol, and adding a small amount of effervescent agent, disintegrating agent, Flavoring agents and lubricants are directly compressed at a lower pressure. Summary of the invention
- the inventors of the present invention have found through research that the donepezil hydrochloride and the disintegrant are mixed, optionally with the addition of an auxiliary material, and the orally disintegrating tablet obtained by directly pressing the mixture into a powder, since the preparation process does not require granulation and drying. Therefore, energy saving and time saving, while reducing the quality instability factor of the drug in the preparation process, the product quality is stable, and is conducive to improving the degree of industrial automation.
- the present invention provides:
- a donepezil hydrochloride orally disintegrating tablet comprising donepezil hydrochloride and a disintegrating agent, which is obtained by directly compressing a mixture of donepezil hydrochloride and a disintegrating agent.
- PVPP crosslinked polyvinylpyrrolidone
- sodium carboxymethyl starch sodium carboxymethyl starch
- CMS-Na low-substituted hydroxypropylcellulose
- L-HPC low-substituted hydroxypropylcellulose
- CCNa croscarmellose sodium
- soybean polysaccharide soybean polysaccharide
- the filler is selected from one or more of mannitol, xylitol, sorbitol, maltose, microcrystalline cellulose, polymeric sugar, glucose, lactose, sucrose, dextrin and starch, and the flavoring agent is selected From mannitol, xylitol, stevioside, lactose, fructose, sucrose, protein sugar, maltitol,
- the glidant is selected from one or more of fine powder silica gel, talc powder and hydrated sodium aluminosilicate.
- the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, glyceryl monostearate, polyethylene glycol, hydrogenated vegetable oil, sodium stearyl fumarate, polyoxyethylene monostearate One or more of ester, monolauric sucrose, sodium lauryl sulfate, lauryl sulfate, sodium lauryl sulfate, and talc,
- the coating material is selected from the group consisting of gelatin, gum arabic, alginate, chitosan, carboxymethyl cellulose salt, cellulose acetate phthalate, ethyl cellulose, decyl cellulose, hydroxypropyl cellulose, One or more of an acrylic resin, polyvinyl alcohol, polyvinylpyrrolidone, and polyethylene glycol.
- a method for preparing a donepezil hydrochloride orally disintegrating tablet characterized in that the direct compression method comprises the following steps:
- a disintegrant with donepezil hydrochloride, optionally adding at least one selected from the group consisting of a filler, a binder, an effervescent agent, a flavoring agent, a glidant, a coating material, and a lubricant And mixing and hooking to obtain a mixture;
- the taste-masking coating of donepezil hydrochloride is selected from the group consisting of gelatin, gum arabic, alginate, Chitosan, carboxymethyl cellulose salt, cellulose acetate phthalate, ethyl cellulose, mercapto cellulose, hydroxypropyl cellulose, acrylic resin, polyvinyl alcohol, polyvinyl pyrrolidone and polyethylene glycol Any one or a mixture of two or more.
- the donepezil hydrochloride orally disintegrating tablet obtained by the method for preparing donepezil hydrochloride orally disintegrating tablet according to the above 7.
- the donepezil hydrochloride orally disintegrating tablet is directly compressed into a tablet by mixing the powder of the drug with a specific disintegrating agent by a powder direct compression technique. Since the production process does not require granulation and drying, energy saving and time saving, and at the same time, the quality instability factor of the medicine in the preparation process is reduced, and the degree of industrial automation is improved.
- the present invention adopts the donepezil hydrochloride orally disintegrating tablet prepared by the direct compression method.
- the low-substituted hydroxypropyl cellulose and the cross-linked polyvinylpyrrolidone are unexpectedly found.
- the disintegrating agent is used together to prepare the donepezil hydrochloride orally disintegrating tablet, and has a synergistic effect, so that the drug achieves a good disintegration effect, and the product quality is stable.
- the donepezil hydrochloride orally disintegrating tablet prepared by the direct compression method has a simple process, and does not pass through granules (wet granules or dry granules), and is energy-saving.
- Time saving, low production cost on the other hand, with the advantages of stable product quality and high industrial automation, it is one of the important ways to accelerate the development of modern tablet preparation technology in China.
- it reduces the cost of equipment and operation; reduces the investment in equipment and plant, as well as inspection cost and labor intensity, saves time and energy, and does not determine the quality of the product due to the experience of the workers, so that the quality of the final product is stable, and the difference between batches is small. It has strong operability and continuous production guarantee, especially suitable for production management of GMP requirements. detailed description
- the donepezil hydrochloride orally disintegrating tablet of the present invention comprises donepezil hydrochloride and a disintegrating agent, which is obtained by directly compressing a mixture of donepezil hydrochloride and a disintegrant.
- Disintegrators for use in the present invention include, but are not limited to, cross-linked polyvinylpyrrolidone (PVPP), sodium carboxymethyl starch (CMS-Na), low-substituted hydroxypropylcellulose (L-HPC), cross-linked carboxy-based fibers.
- PVPP cross-linked polyvinylpyrrolidone
- CMS-Na sodium carboxymethyl starch
- L-HPC low-substituted hydroxypropylcellulose
- CCNa carboxymethyl starch
- L-HPC low-substituted hydroxypropylcellulose
- EMCOSOY® soybean polysaccharide
- PVPP Polyvinylpyrrolidone
- L-HPC Low-substituted hydroxypropylcellulose
- the L-HPC powder has a large specific surface area and porosity, and thus has a large moisture absorption rate and water absorption.
- the present invention discloses a donepezil hydrochloride orally disintegrating tablet and a preparation method thereof. It is prepared by a specific method, consisting of one or more of donepezil hydrochloride, a filler, a disintegrant, a flavoring agent, a binder, an effervescent agent, a glidant, a lubricant, and a coating material.
- the prescription composition is as follows: in a weight ratio, donepezil hydrochloride is 2-50%, preferably 2-20%, more preferably 3-15%, further preferably 3-12%, still more preferably 5-7%;
- the agent is 10 - 90%, preferably 10 - 80%, more preferably 70 - 80%;
- the disintegrant is 2 - 35%, preferably 3 - 30%, more preferably 5-18%;
- the flavoring agent is 1 - 40%, preferably 2 -4%; binder 0-10%, effervescent 0-30%, glidant 0.01-5%, lubricant 0.3-3%, coating material 0-40%.
- the mixing ratio of the crosslinked polyvinylpyrrolidone to the low-substituted hydroxypropylcellulose is by weight. It is 0.1: 1 - 1: 0.1, preferably 1: 1.5 - 1: 1.
- the prepared orally disintegrating tablet has the characteristics of good permeability and high mechanical strength, and the disintegration time is 1 to 60 seconds, preferably 10 to 20 seconds.
- the various excipients described in the present invention are characterized by the following selection categories:
- Binders include, but are not limited to, starch, pregelatinized starch, dextrin, maltodextrin, sucrose, gum arabic, decyl cellulose, carboxymethyl cellulose, ethyl cellulose, polyvinyl alcohol, polyethylene glycol , polyvinylpyrrolidone (PVP), alginic acid and alginate, xanthan gum and hydroxypropyl methylcellulose (HPMC), either alone or in combination.
- the pregelatinized starch is a product obtained by physically destroying the starch structure to partially gel the starch, and is stable to a white dry powder.
- Fillers include, but are not limited to, mannitol (granular or powder), xylitol, sorbitol, maltose, microcrystalline cellulose, polymeric sugars (eg, EMDEX®), glucose, lactose, sucrose, dextrin, and starch. They can be used alone or in combination, and the dosage is usually (10-80)%.
- Disintegrants including but not limited to cross-linked polyvinylpyrrolidone (PVPP), sodium carboxymethyl starch (CMS-Na), low-substituted hydroxypropyl cellulose (L-HPC), croscarmellose sodium (CCNa) and soybean polysaccharide (for example, EMCOSOY®), etc., may be used singly or in combination.
- PVPP cross-linked polyvinylpyrrolidone
- CMS-Na sodium carboxymethyl starch
- L-HPC low-substituted hydroxypropyl cellulose
- CCNa croscarmellose sodium
- soybean polysaccharide for example, EMCOSOY®
- Flavoring agents including but not limited to mannitol, xylitol, stevioside, lactose, fructose, sucrose, glucosamine, maltitol, glycyrrhizin, sodium cyclamate, gelatin, aspartame, banana Flavor, pineapple flavor, vanillin, orange flavor, orange flavor, mint flavor, ginseng flavor, strawberry flavor, citric acid, citric acid, etc., may be used singly or in combination.
- Glidants including but not limited to micronized silica gel, talcum powder, Cab-0-sil,
- ArosiK hydrated sodium aluminosilicate, etc. can be used singly or in combination.
- Lubricants including but not limited to magnesium stearate, calcium stearate, zinc stearate, glyceryl monostearate, polyethylene glycol, hydrogenated vegetable oil, sodium stearyl fumarate, polyoxyethylene single hard
- the fatty acid ester, monolauric sucrose ester, sodium lauryl sulfate, lauryl sulfate, sodium lauryl sulfate and talc may be used singly or in combination.
- Coating materials including but not limited to gelatin, gum arabic, alginate, chitosan, carboxymethyl cellulose salts, cellulose acetate phthalate, ethyl cellulose, methyl cellulose, hydroxypropyl hydrazine fiber , acrylic resin (domestic acrylic resin I, II, III, IV, Eudragit® series), polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycol, etc., may be used singly or in combination.
- the donepezil hydrochloride orally disintegrating tablet of the present invention is obtained by mixing donepezil hydrochloride with a disintegrating agent, and directly compressing the mixture into a powder.
- the preparation method of the donepezil hydrochloride orally disintegrating tablet of the present invention is characterized in that the direct compression method comprises the following steps: (1) uniformly mixing the disintegrant with donepezil hydrochloride, optionally adding a filler selected from a filler. Mixing at least one of a mixture, an effervescent agent, a flavoring agent, a glidant, a coating material and a lubricant to obtain a mixture; (2) feeding the mixture obtained in the above (1) to a tableting machine That is.
- the method for preparing a donepezil hydrochloride orally disintegrating tablet according to the present invention is characterized by the following steps:
- the preparation method of the present invention is characterized in that: donepezil hydrochloride can be treated in advance.
- the preparation method of the present invention is characterized in that: a taste masking coating can be applied to donepezil hydrochloride, and the coating material used for taste masking treatment is gelatin, gum arabic, alginate, Chitosan, carboxymethyl cellulose salt, cellulose acetate phthalate, ethyl cellulose, decyl cellulose, hydroxypropyl cellulose, acrylic resin (domestic acrylic resin I, II, III, IV, Eudragit ® series), a mixture of any one or a mixture of two or more of polyvinyl alcohol, polyvinylpyrrolidone, and polyethylene glycol.
- the coating material used for taste masking treatment is gelatin, gum arabic, alginate, Chitosan, carboxymethyl cellulose salt, cellulose acetate phthalate, ethyl cellulose, decyl cellulose, hydroxypropyl cellulose, acrylic resin (domestic acrylic resin I, II, III, IV, Eudragit ® series), a mixture of any one
- any one of the preparation methods of the present invention is characterized in that: an auxiliary effervescent agent may be added depending on the case.
- the effervescent agent of the present invention is characterized in that the excipient is a mixture of malic acid or citric acid, with sodium hydrogencarbonate or sodium carbonate.
- the method for preparing a donepezil hydrochloride orally disintegrating tablet according to the present invention is characterized in that the obtained tablet has a hardness of between 10 and 45 Newtons, and the disintegration time is within 1 to 60 seconds. .
- the preparation method of the donepezil hydrochloride orally disintegrating tablet according to the present invention is characterized in that it adopts a direct compression method.
- PVPP-XL cross-linked polyvinylpyrrolidone
- L-HPC-1 1 low-substituted hydroxypropylcellulose
- Donepezil Chongqing Sangtian Pharmaceutical Co., Ltd.
- Aspatan Jiangsu Niutang Chemical No.
- donepazil hydrochloride is dissolved in 5ml water, heated in a water bath at 60 °C, and fully dissolved. This solution is made into soft material made of mannitol, sieved by 30 mesh, dried at 60 °C, and sieved into 20 mesh. PVPP, L-HPC, and aspartame were mixed and added with magnesium stearate.
- the time limit for determining the disintegration is:
- Method 1 Small beaker method: Take 1 5ml small beaker, force. 2 ml of 7j, the tablets were placed therein, and the disintegration time of the tablets was recorded.
- Method 2 Instrument test method: In order to solve the shortcomings of the disintegration frequency of the disintegration instrument used in the current Chinese Pharmacopoeia's current disintegration time limit determination method, it is also determined by reference to some disintegration time limits mentioned in the foreign orally disintegrating tablets patent. Method, the present invention utilizes the existing Chinese Pharmacopoeia 2000 version of the two dissolution tester and the lift basket of the lift disintegration instrument. Before The speed can be adjusted.
- the orally disintegrating tablet of the present invention (take the comparative example 2, the sample of the sample 1-3, respectively), according to the guiding principle of the drug stability test, respectively, using a high temperature test: the test product is placed in a sealed clean container at 60 ° C The test was carried out on the 5th day and the 10th day after being placed for 10 days.
- High-humidity test The test sample was placed in a constant-humidity closed container and placed at 25 °C, RH90 % ⁇ 5 % for 10 days, and samples were taken on the 5th and 10th days.
- 3 Illumination test The test sample is placed in a light box or other suitable light container, placed under the illumination of 4500Lx ⁇ 500Lx for 10 days, and sampled on the 5th and 10th day.
- Disintegration time limit measurement method Take 6 cups of 50 ml beakers, place them in a water bath at 37 °C, add 2 ml of water, place for 10 minutes, and equilibrate the temperature. Take 6 samples of Comparative Example 2 and Example 1-3, respectively, and add them to each beaker. , statically placed, after 60 seconds, the dispersion suspension is poured into a 24 mesh sieve (No. 2 sieve), and the particles should pass completely.
- Example 1-3 samples, according to the dissolution method (Chinese Pharmacopoeia 2005 edition two appendix XC second method), using water 100ml as the dissolution medium, the rotation speed is 50 rpm, according to the law, by At 30 minutes, take the appropriate amount of the solution, filter it, as the test solution; take the appropriate amount of donepezil hydrochloride reference substance, add the dissolution medium to dissolve, so that the concentration is about 0.05mg / ml, as a reference solution. Separately measure 20 ⁇ 1 of each of the above two solutions, and measure according to the method of content determination. The detection wavelength is 271 nm, and the dissolution amount of each piece is calculated to obtain the dissolution degree (%;).
- the impurity content is calculated by the external standard method according to the peak area, and the area of any impurity peak should not exceed 50% of the main peak area of the control solution, and the sum of the peak areas of the impurities Do not exceed the main peak area of the control solution.
- the donepezil hydrochloride orally disintegrating tablet is directly compressed into a tablet by mixing the powder of the drug with a specific disintegrating agent by a powder direct compression technique.
- the donepezil hydrochloride orally disintegrating tablet prepared by the direct compression method is compared with the traditional tablet production process by wet granulation, because the production process does not need granulation and drying, so energy saving and time saving, the production cost is low, and the other In terms of products, it has the advantages of stable product quality and high industrial automation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Description
盐酸多奈哌齐口腔崩解片及其制备方法 技术领域
本发明涉及一种盐酸多奈哌齐口腔崩解片及其制备方法,具体 来说, 涉及一种含有盐酸多奈哌齐的口腔崩解片及其制备方法。 所述的盐酸多奈哌齐口腔崩解片可用于治疗阿尔茨海默症。 背景技术
盐酸多奈哌齐(Donepezil Hydrochloride)是第二代治疗阿尔茨 海默病的胆碱酯酶抑制剂( AChEI) , 对神经元乙酰胆碱酯酶选择性 强, 它通过抑制乙酰胆碱脂酶增加动物大脑乙酰胆碱含量, 使直 接参与神经传递的突触间中的乙酰胆碱含量增加, 产生治疗效果, 可以改善学习障碍.对心脏和肠的乙酰胆减酯酶几乎没有抑制作 用, 因此选择性强, 作用时间长,副作用小, 无肝脏毒性等特点. 是 治疗早老型痴呆较为理想的药物。
口腔崩解片即在口腔内可快速崩解、分散或溶解于唾液中的片 剂, 患者不需用水或只需少量用水, 也无需咀嚼, 药物置于口腔 内, 遇唾液迅速溶解或崩解后, 随着服用者的自主及不自主的吞 咽动作进入消化系统吸收后起效。 方便部分人群用药, 如老人、 儿童、 吞咽困难或特殊环境下的病人用药, 该剂型与普通片剂相 比, 可提供一种新的服用方法。
对于较苦涩的药物, 在开发口崩片时, 矫味是处方筛选的重点 项目之一。 现有技术中, 一般采用甜味剂或香精进行矫味。 但对 于有些臭味较大的药物, 单纯加入大量的甜味剂有时也难以达到 满意的效果。 采用药物 - 离子交换树脂形成的复合物是较成功的 矫味技术, 该复合物通过药物与离子交换树脂在一定的 pH条件下 进行喷雾干燥而得到。 在唾液近中性的 pH环境下, 药物不易从交 换树脂置换, 但在胃酸中, 通过氢离子的交换作用而使药物脱离 交换树脂游离出来, 从而较好的解决药物苦涩的问题。 此外粉末 包衣技术的应用也能较好的解决药物的不良臭味。 所以科学合理 的设计矫味技术在开发口崩片中显得格外重要。
目前国内外制备口腔崩解片的技术有:冷冻干燥压片技术及在
国内广泛使用的一般粉末制颗粒压片技术。 从制备的口崩片的标 准看, 冷冻干燥压片制得的口崩片质地疏松, 崩解时限一般在 15 秒内, 但该技术属专利技术, 难以广泛使用。 采用湿法制粒压片 技术制备的口崩片, 为获得快速崩解的效果, 通常在处方中添加 大量的崩解剂 (一般采用内外加法) , 此种制备方法制得的崩解 片虽然在崩解时限可以达到要求, 但由于压片力较大, 片剂较硬, 崩解时限一般时间较长, 而且口感较差, 崩解剂在吸水膨胀后粘 附在口腔里, 不可避免需要借助喝水吞服药物。 这样就失去了崩 解剂的最大的优点, 同时也可能由于药物的苦涩, 造成服药的顺 应性较差。
作为一种适应特殊人群用药的新剂型, 口腔崩解片的研究与应 用已成为医药领域的热点之一。
在盐酸多奈哌齐口腔崩解片研究过程中发现,片剂崩解性能的 优化可用崩解剂的临界浓度来确定, 低于临界浓度时, 崩解时间 与崩解剂浓度成反比; 高于临界浓度后, 崩解时间基本保持不变。 低取代羟丙基纤维素 ( L-HPC )有不同粒径、 不同取代度等许多级 别, 不同级别的崩解特性也不同。 其中 L-HPC-1 1 为中等取代度, 粒径最大,主要用于防止片剂顶裂和直接压片的崩解剂; L-HPC-21 主要用于湿法制粒片剂的黏合剂和崩解剂; L-HPC-31 为颗粒度较 小的级别, 较易通过网筛, 主要用于挤出制粒。
由于口腔崩解片存在片剂硬度较小、 脆碎度较高的缺点, 因此 在其制备工艺中选择合适崩解剂及赋形剂显得尤其重要。 发明人 将 D-甘露醇和交联聚乙烯吡咯烷酮 (PVPP ) 制成复合崩解剂, 通 过直接压片法制备口腔崩解片, 结果具有良好的崩解特性, 但是 片剂硬度较大。 其中, 经碾磨的 D-甘露醇比普通甘露醇颗粒小, 圆形度和表面积增大, 从而单位面积内镶嵌点增多, 使片剂硬度 增大。
目前, 通常采用冷冻干燥法 ( Zydis 法) 和 Orasolv 法。 其中 Zydis法与普通的冻干方法, 例如粉针冻干工艺不同, 主要是将主 药和辅料定量分装在一定模具中, 冻干去水, 制得高孔隙率的固 体制剂。 而 Orasolv法亦是采取先以明胶、 微晶纤维素包裹主药成 小颗粒掩味, 加入较多量的甘露醇, 另加入少量泡腾剂、 崩解剂、
矫味剂以及润滑剂, 以较小压力直接压片而成。 发明内容
本发明的发明人通过努力研究发现,将盐酸多奈哌齐与崩解剂 混合均勾, 任选地加入辅料, 将混合物直接粉末压片得到的口腔 崩解片, 由于其制作过程不需制粒、 干燥, 所以节能省时, 同时 减少了药物在制备过程中质量不稳定性因素, 产品质量稳定, 有 利于提高工业自动化程度等。
更具体地, 本发明提供:
1. 一种盐酸多奈哌齐口腔崩解片, 其包含盐酸多奈哌齐和崩 解剂, 其特征在于: 将盐酸多奈哌齐和崩解剂的混合物直接粉末 压片获得。
2. 根据上述 1 所述的盐酸多奈哌齐口腔崩解片, 其特征在于: 还包含选自填充剂、 矫味剂、 粘合剂、 泡腾剂、 助流剂、 润滑剂 或包衣材料中的至少一种, 以重量比计, 盐酸多奈哌齐 2— 50%, 填充剂 10— 80%,崩解剂 2— 35%,矫味剂 1一 40%,粘合剂 0— 10%, 泡腾剂 0— 30%, 助流剂 0.01— 5% , 润滑剂 0.3— 3%, 包衣材料 0—40%, 总量为 100%。
3. 根据上述 1所述的盐酸多奈哌齐口腔崩解片, 其特征在于: 所述崩解剂选自交联聚乙烯吡咯烷酮 ( PVPP) 、 羧曱基淀粉钠
( CMS-Na) 、 低取代羟丙基纤维素 (L-HPC) 、 交联羧曱基纤维 素钠 (CCNa) 和大豆多糖中的一种或多种。
4. 根据上述 3所述的盐酸多奈哌齐口腔崩解片, 其特征在于: 所述崩解剂是交联聚乙烯吡咯烷酮和低取代羟丙基纤维素的混合 物。
5. 根据上述 4 所述的盐酸多奈哌齐口腔崩解片, 其特征在于 获得的片剂的硬度在 10至 45牛顿, 崩解时间在 1 - 60秒。
6. 根据上述 2所述的盐酸多奈哌齐口腔崩解片, 其特征在于: 所述粘合剂选自淀粉、 预胶化淀粉、 糊精、 麦芽糖糊精、 蔗糖、 阿拉伯胶、 曱基纤维素、 羧曱基纤维素、 乙基纤维素、 聚乙烯醇、 聚乙二醇、 聚乙烯吡咯烷酮 ( PVP) 、 海藻酸及海藻酸盐、 黄原胶 和羟丙基曱基纤维素 ( HPMC) 中的一种或多种,
所述填充剂选自甘露醇、 木糖醇、 山梨醇、 麦芽糖、 微晶纤维 素、 聚合糖、 葡萄糖、 乳糖、 蔗糖、 糊精和淀粉中的一种或多种, 所述矫味剂选自甘露醇、 木糖醇、 甜菊甙、 乳糖、 果糖、 蔗糖、 蛋白糖、 麦芽糖醇、 甘草甜素、 环己氨基磺酸钠、 明胶、 阿司帕 坦、 香蕉香精、 菠萝香精、 香兰素、 香橙香精、 桔子香精、 薄荷 香精、 人参香精、 草莓香精和柠檬酸中的一种或多种,
所述助流剂选自微粉硅胶、滑石粉和水合硅铝酸钠中的一种或 多种,
所述润滑剂选自硬脂酸镁、 硬脂酸钙、 硬脂酸辞、 单硬脂酸甘 油脂、 聚乙二醇、 氢化植物油、 硬脂富马酸钠、 聚氧乙烯单硬脂 酸酯、 单月桂蔗糖酸酯、 月桂醇硫酸钠、 月桂醇硫酸妹、 十二烷 基硫酸镁和滑石粉中的一种或多种,
所述包衣材料选自明胶、 阿拉伯胶、 海藻酸盐、 壳聚糖、 羧甲 基纤维素盐、 醋酸纤维素酞酸酯、 乙基纤维素、 曱基纤维素、 羟 丙曱纤维素、 丙烯酸树脂类、 聚乙烯醇、 聚乙浠吡咯烷酮和聚乙 二醇中的一种或多种。
7. 一种盐酸多奈哌齐口腔崩解片的制备方法, 其特征在于, 采用直接压片法, 包含以下步骤:
( 1 ) 将崩解剂与盐酸多奈哌齐混合均勾, 任选地加入选自填充 剂、 粘合剂、 泡腾剂、 矫味剂、 助流剂、 包衣材料和润滑剂中的 至少一种并混合均勾, 得到混合物;
(2) 将上述 ( 1 ) 所得混合物送入压片机压片即得。
8. 根据上述 7 所述的盐酸多奈哌齐口腔崩解片制备方法, 其 特征在于: 对盐酸多奈哌齐进行掩味包衣, 用于掩味处理的包衣 材料选自明胶、 阿拉伯胶、 海藻酸盐、 壳聚糖、 羧曱基纤维素盐、 醋酸纤维素酞酸酯、 乙基纤维素、 曱基纤维素、 羟丙曱纤维素、 丙烯酸树脂类、 聚乙烯醇、 聚乙烯吡咯烷酮和聚乙二醇任意一种 或两种以上的混合物。
9. 根据上迷 7 所述的盐酸多奈哌齐口腔崩解片制备方法, 其 中, 泡腾剂选自苹果酸或拧檬酸、 与碳酸氢钠或碳酸钠的混合物。
10. 由上述 7所述的盐酸多奈哌齐口腔崩解片制备方法得到的 盐酸多奈哌齐口腔崩解片。
盐酸多奈哌齐口腔崩解片采用粉末直接压片技术,将药物的粉 末与特定的崩解剂混合后直接压制成片。 由于其制作过程不需制 粒、 干燥, 所以节能省时, 同时减少了药物在制备过程中质量不 稳定性因素, 有利于提高工业自动化程度等。
本发明采用直接压片法制备的盐酸多奈哌齐口腔崩解片,在研 发过程中, 在一种优选的实施方式中, 意外发现将低取代羟丙基 纤维素和交联聚乙烯基吡咯烷酮此两种崩解剂一同用于制备盐酸 多奈哌齐口腔崩解片, 具有协同作用, 使得该药物实现很好的崩 解效果, 并且产品质量稳定。
本发明采用直接压片法制备的盐酸多奈哌齐口腔崩解片与传 统的片剂生产工艺湿法制粒相比, 粉末直接压片工艺有着工艺简 单, 不经过制颗粒(湿颗粒或干颗粒), 节能省时, 生产成本低, 另 一方面, 具有产品质量稳定, 工业自动化程度高等优点, 是加速 我国现代片剂制备技术发展的重要途径之一。 同时降低了设备和 运作的成本; 减少了相应的设备厂房投资以及检验成本和劳动强 度, 节约时间和能源, 且不因工人的经验决定产品的质量, 使最 终产品质量稳定, 批次间差异小, 可操作性强, 连续生产有保证, 尤其适合 GMP 要求的生产管理。 具体实施方式
本发明的盐酸多奈哌齐口腔崩解片,其包含盐酸多奈哌齐和崩 解剂, 其特征在于: 将盐酸多奈哌齐和崩解剂的混合物直接粉末 压片获得。
本发明所用的崩解剂包括但不仅限于交联聚乙烯吡咯烷酮 ( PVPP ) 、 羧曱基淀粉钠 ( CMS-Na ) 、 低取代羟丙基纤维素 ( L-HPC ) 、 交联羧曱基纤维素钠 ( CCNa ) 和大豆多糖 (例如, EMCOSOY® ) 等, 可单独使用, 也可组合使用。 优选交联聚乙烯 吡咯烷酮与低取代羟丙基纤维素的混合物。
交联聚乙烯基吡咯烷酮 (PVPP ) 是白色或近白色的具有吸湿 性易流动的粉末, 无臭或微臭, 不溶于水、 碱、 酸及常用有机溶 剂, 具有很强的膨胀性能和与多类物质的络合能力。 由于 PVPP的 高分子量和交联结构, 不溶于水但遇水能迅速将水引入, 促使其
网络结构膨胀产生崩解作用, 所以 PVPP 是医药上广泛应用于片 剂、 颗粒剂及胶嚢剂的崩解剂、 填充剂。
低取代羟丙基纤维素 (L-HPC) 为白色或类白色结晶性粉末, 在水中不溶但可以吸水溶胀。 L-HPC 粉末具有^ [艮大比表面积和孔 隙率, 从而具有较大的吸湿速度和吸水量。
进一步地,本发明公开了一种盐酸多奈哌齐口腔崩解片及其制 备方法。 由盐酸多奈哌齐、 填充剂、 崩解剂、 矫味剂、 粘合剂、 泡腾剂、 助流剂、 润滑剂、 包衣材料中的一种或一种以上组成, 经特定的方法制备而成, 其特征在于其处方组成如下: 以重量比 计, 盐酸多奈哌齐 2— 50%, 优选 2-20%, 更优选 3-15% , 进一步 优选 3-12%,再进一步优选 5-7%;填充剂 10 - 90%,优选 10— 80%, 更优选 70 - 80% ; 崩解剂 2— 35%, 优选 3-30%, 更优选 5-18%; 矫味剂 1一 40%, 优选 2-4% ; 粘合剂 0— 10%, 泡腾剂 0— 30%, 助流剂 0.01— 5% , 润滑剂 0.3— 3%, 包衣材料 0— 40%。
本发明的优选实施方式中,使用交联聚乙烯吡咯烷酮与低取代 羟丙基纤维素的混合物作为崩解剂时, 交联聚乙烯吡咯烷酮与低 取代羟丙基纤维素的混合比例以重量比计为 0.1: 1 - 1: 0.1, 优选 为 1: 1.5- 1: 1。
本发明的优选实施方式中, 所制备的口腔崩解片具有渗透性 好、 机械强度高的特点, 崩解时间为 1 ~60秒, 优选 10~20 秒。
本发明的优选实施方式中, 本发明所述的各种辅料, 其特征在 于各自的选择种类如下:
粘合剂 包括但不仅限于淀粉、 预胶化淀粉、 糊精、 麦芽糖 糊精、 蔗糖、 阿拉伯胶、 曱基纤维素、 羧甲基纤维素、 乙基纤维 素、 聚乙烯醇、 聚乙二醇、 聚乙烯吡咯烷酮 (PVP) 、 海藻酸及海 藻酸盐、 黄原胶和羟丙基甲基纤维素 (HPMC) , 可单独使用, 也 可组合使用。 预胶化淀粉是淀粉经过物理方法破坏淀粉构造使部 分胶化得到的产品, 为白色干燥粉末性质稳定。
填充剂 包括但不仅限于甘露醇 (粒状或粉状) 、 木糖醇、 山梨醇、 麦芽糖、 微晶纤维素、 聚合糖 (例如, EMDEX®) 、 葡萄 糖、 乳糖、 蔗糖、 糊精和淀粉等, 可以单独使用, 也可以组合应 用, 用量通常为 ( 10— 80) %。
崩解剂——包括但不仅限于交联聚乙烯吡咯烷酮 (PVPP ) 、 羧曱基淀粉钠 (CMS-Na ) 、 低取代羟丙基纤维素 ( L-HPC ) 、 交 联羧甲基纤维素钠( CCNa )和大豆多糖(例如, EMCOSOY® )等, 可单独使用, 也可组合使用。
矫味剂——包括但不仅限于甘露醇、 木糖醇、 甜菊甙、 乳糖、 果糖、 蔗糖、 蛋白糖、 麦芽糖醇、 甘草甜素、 环己氨基磺酸钠、 明胶、 阿司帕坦、 香蕉香精、 菠萝香精、 香兰素、 香橙香精、 桔 子香精、 薄荷香精、 人参香精、 草莓香精、 枸橼酸、 柠檬酸等, 可单独使用, 也可组合使用。
助流剂——包括但不仅限于微粉硅胶、 滑石粉、 Cab-0-sil、
ArosiK 水合硅铝酸钠等, 可单独使用, 也可组合使用。
润滑剂——包括但不仅限于硬脂酸镁、 硬脂酸钙、 硬脂酸锌、 单硬脂酸甘油脂、 聚乙二醇、 氢化植物油、 硬脂富马酸钠、 聚氧 乙烯单硬脂酸酯、 单月桂蔗糖酸酯、 月桂醇硫酸钠、 月桂醇硫酸 妹、 十二烷基硫酸镁和滑石粉等, 可单独使用, 也可组合使用。
包衣材料——包括但不仅限于明胶、 阿拉伯胶、 海藻酸盐、 壳 聚糖、 羧曱基纤维素盐、 醋酸纤维素酞酸酯、 乙基纤维素、 甲基 纤维素、 羟丙曱纤维素、 丙烯酸树脂类(国产丙烯酸树脂 I、 II、 III、 IV , Eudragit®系列) 、 聚乙烯醇、 聚乙烯吡咯烷酮、 聚乙二醇等, 可单独使用, 也可组合使用。
本发明的盐酸多奈哌齐口腔崩解片是将盐酸多奈哌齐与崩解 剂混合均勾, 将混合物直接粉末压片得到的。
本发明的盐酸多奈哌齐口腔崩解片的制备方法, 其特征在于, 采用直接压片法, 包含以下步骤: (1 ) 将崩解剂与盐酸多奈哌齐混 合均匀, 任选地加入选自填充剂、 粘合剂、 泡腾剂、 矫味剂、 助 流剂、 包衣材料和润滑剂中的至少一种并混合均匀, 得到混合物; (2) 对上述 ( 1 ) 所得混合物送入压片机压片即得。
本发明的优选实施方式中,本发明所述的盐酸多奈哌齐口腔崩 解片的制备方法, 其特征在于由以下步骤组成:
( 1 ) 将交联聚乙烯吡咯烷酮与低取代羟丙基纤维素混合均匀, 再加入适量的盐酸多奈哌齐与阿司帕坦混合均勾,再按等量递增法 加入除硬脂酸镁外其它辅料混合均匀, 加入润滑剂混匀备用;
(2) 所得物料经中间体检测, 确定片重后, 送入压片机压片即 付。
本发明的优选实施方式中, 本发明所述的制备方法, 其特征在 于: 可以预先对盐酸多奈哌齐进行处理。
本发明的优选实施方式中, 本发明所述及的制备方法, 其特征 在于: 可以对盐酸多奈哌齐进行掩味包衣, 用于掩味处理的包衣 材料是明胶、 阿拉伯胶、 海藻酸盐、 壳聚糖、 羧甲基纤维素盐、 醋酸纤维素酞酸酯、 乙基纤维素、 曱基纤维素、 羟丙曱纤维素、 丙烯酸树脂类 (国产丙烯酸树脂 I、 II、 III、 IV, Eudragit®系列) 、 聚乙烯醇、 聚乙烯吡咯烷酮、 聚乙二醇等任意一种或两种以上的 混合物。
本发明的优选实施方式中, 本发明所述及的任何一种制备方 法, 其特征在于: 根据情况还可加入辅料泡腾剂。
本发明的优选实施方式中, 本发明所述及的泡腾剂, 其特征在 于: 该辅料是苹果酸或柠檬酸、 与碳酸氢钠或碳酸钠的混合物。
本发明的优选实施方式中,本发明所述及的盐酸多奈哌齐口腔 崩解片的制备方法, 其特征在于获得的片剂的硬度在 10 至 45 牛 顿之间, 崩解时间在 1 - 60秒内。
本发明所述及的盐酸多奈哌齐口腔崩解片的制备方法,其特征 在于其采用直接压片法制备工艺。 实施例
实施例 1
处方: 表 1 盐酸多奈哌齐 5g
甘露醇 100g
PVPP-XL 3.8g
L-HPC- 1 1 3.8g
微晶纤维素 101 35g
阿司帕坦 1.9g
硬脂酸镁 2- 5g
制备工艺:
将交联聚乙烯吡咯烷酮 (PVPP-XL , 上海运宏药用辅料公司 ) 与低取代羟丙基纤维素 (L-HPC-1 1 , 湖州药用辅料厂) 混合均匀, 再加入上述处方量盐酸多奈哌齐 (重庆桑田药业有限公司 ) 与阿 司帕坦 (江苏牛塘化工二厂) 混合均勾, 再按等量递增法加入除 硬脂酸镁外其它辅料 (甘露醇, 上海辅力膜敷料有限公司; 微晶 纤维素 101 , 美国诺誉化工) 混合均匀, 加入上述处方量硬脂酸镁 (上海运宏药用辅料公司 ) 混合均勾后压片。 实施例 2
处方: 表 2
按照表 2所示处方,与实施例 1 同样地得到盐酸多奈哌齐口腔 崩解片。
实施例 3
处方:
按照表 3所示处方,与实施例 1 同样地得到盐酸多奈哌齐口腔 崩解片。 实施例 4
处方: 表 4
按照表 4所示处方,与实施例 1 同样地得到盐酸多奈哌齐口腔 崩解片。 实施例 5
表 5 盐酸多奈哌齐 10g
乳糖 Granulac200 40g
PVPP-XL-10 7 g
L-HPC-11 5g
阿司帕坦 4g
硬脂酸镁 5g
制成 1000片 制备工艺:
按照表 5所示处方,与实施例 1 同样地得到盐酸多奈哌齐口腔 崩解片。 其中, 交联聚乙烯吡咯烷酮 (PVPP-XL-10, 上海运宏药 用辅料公司 ) , 乳糖使用乳糖 Granulac200 (上海辅力膜敷料有限 公司 ) 。 实施例 6
处方: 表 6
按照表 6所示处方,与实施例 1 同样地得到盐酸多奈哌齐口腔 崩解片。
比较例 1
处方:
将微晶纤维素、 甘露醇、 盐酸多奈哌齐混合, 以水制软材, 用
30 目 筛制粒, 60 °C烘干, 20 目 筛整粒, 加入除硬脂酸镁外的其他 辅料, 均勾混合后加入硬脂酸镁混勾压片。 比较例 2
处方: 表 8
80 目筛 3次, 加入甘露醇, 用水制软材, 30 目筛制粒, 60 °C供干, 20 目筛整粒后加入 PVPP、 L-HPC、 阿司帕坦混匀, 加入硬脂酸镇 混合压片。 比较例 3
处方: 表 9
通过对乙醇、 水的实验, 发现盐酸多奈哌齐在热水中溶解度有 很大提高, 且冷却后不复析出, 所以采用热水溶解。
先将盐酸多奈哌齐溶解在 5ml水中, 60 °C水浴, 搅拌, 使之全 溶, 将此溶液与甘露醇制软材, 30 目 筛制粒, 60 °C烘干, 20 目 筛 整粒后加入 PVPP、 L-HPC、 阿司帕坦混匀, 加入硬脂酸镁混合压 片。
对实施例 1 -3 和比较例 1 -3 的口腔崩解片的基本性能进行考 察。
其中崩解时限测定法为:
方法 1 : 小烧杯法: 取 1 只 5ml小烧杯, 力。 2ml 7j , 将片置于 其中, 记录片剂的崩解时间。
方法 2 : 仪器测试法: 为了解决中国药典现行的崩解时限测定 方法中使用的崩解仪的升降频率是固定的这一缺点, 同时参考国 外口崩片专利中提及的一些崩解时限测定方法, 本发明利用现有 的中国药典 2000版二部溶出度测定仪及升降式崩解仪的吊篮。 前
者是可以调节转速的。
测定: 将溶出仪随机配备的烧杯置于溶出度测定仪的 37摄氏 度恒温水浴中, 注入 750 毫升水, 将吊篮通过篮轴安装于溶出度 测定仪上, 将吊篮浸入水中, 使^篮底距离烧杯底 5 厘米, 取本 品, 置于吊篮的玻璃管中。 启动转轴同时计时, 转速为每分钟 50 或 80转, 片剂颗粒全部通过筛网的时间为崩解时间, 记录崩解时 间。 表 10 盐酸多奈哌口腔崩解片处方基本性能考察结果 实施例 崩解时间 (秒)
硬度 片重差异 仪器法 仪器法
( N ) ( RSD/% ) ( 50rpm ) ( 80rpm ) 比较例 1 26 26 24 23 1.91 比较例 2 28 34 26 22 1.31 比较例 3 27 20 21 25 2.26 实施例 1 32 23 30 24 2. 14 实施例 2 22 20 19 24 1.90 实施例 3 23 21 22 23 1.30 测定结果表明,本发明盐酸多奈哌口腔崩解片具有优异的制剂 学效果。
本发明的口腔崩解片 (分别取比较例 2、 实施例 1 -3样品), 按 照药物稳定性试验指导原则, 分别用①高温试验: 供试品置密封洁 净容器中, 在 60 °C条件下放置 10天, 于第 5天和第 10天取样检测。 ②高湿试验: 供试品置恒湿密闭容器中, 于 25 °C、 RH90 % ± 5 %条 件下放置 10天, 在第 5天和第 10天取样检测。 ③光照试验: 供试品 置光照箱或其它适宜的光照容器内, 于照度 4500Lx ± 500Lx条件下 放置 10天, 在第 5天和第 10天取样检测。
崩解时限测定方法
取 50ml的烧杯 6只,置 37 °C的水浴中,各加水 2ml ,放置 10 分 钟, 使温度平衡, 分别取比较例 2、 实施例 1 -3样品各 6片分别加 入每只烧杯中, 计时, 静态放置, 60 秒后,将分散悬浊液倾倒入 24 目筛 (二号筛) ,颗粒应完全通过。
溶出度测定方法
分别取比较例 2、 实施例 1 -3样品, 照溶出度测定法(中国药典 2005年版二部附录 X C第二法), 以水 100ml为溶出介质, 转速为 每分钟 50 转, 依法操作, 经 30 分钟时, 取溶液适量, 滤过, 作 为供试品溶液; 另取盐酸多奈哌齐对照品适量,加溶出介质溶解,使 浓度约为 0.05mg/ml,作为对照品溶液。分别精密量取上述两种溶液 各 20μ1,照含量测定项下的方法测定, 检测波长为 271 nm, 计算每 片的溶出量, 得到溶出度 ( % ;) 。
有关物质测定方法 (参照国家药品标准 WS 1-(X-140)-2004Z ) 色谱条件: 用十八烷基硅烷键合硅胶为填充剂; 流动相: 醋酸 钠 (0.05mol/L ) - 2.25 %醋酸 - 乙腈 ( 33 : 33 : 34三乙胺调 PH = 7.0 ) , 检测波长: 271 nm。
取约盐酸多奈哌齐 10mg精密称定, 置 10ml容量瓶中, 流动 相溶解,摇匀过滤,续滤液作供试液;精密量取供试液 1 ml置 100ml 量瓶中, 流动相至刻度。 摇勾作为对照溶液。 取供试液、 对照液 各 20μ1 , 分别进样, 采集时间大于主峰保留时间两倍, 记录色谱 图。 以对照溶液所得的主成分峰面积的 5%作为最小积分峰面积, 按外标法以峰面积计算杂质含量, 任一杂质峰面积不得超过对照 溶液主峰面积的 50% , 各杂质峰面积的和不得大于对照溶液的主 峰面积。
盐酸多奈哌齐含量测定方法
照高效液相色谱法(中国药典 2005年版 附录 V D)测定。
色谱条件与系统适用性试验 用十八烷基硅烷键合硅胶为填 充剂; 0.05mol/L 乙酸钠: 2.25 %的乙酸: 乙腈( 33 : 33 : 34 ) (用 三乙胺调 PH值 7.0 ) 为流动相; 检测波长为 271nm。 理论板数按 盐酸多奈哌齐峰计算应不低于 3000。
分别取比较例 2、 实施例 1 -3样品各 20片, 精密称定, 研细, 精密称取适量(约相当于盐酸多奈哌齐 10mg ), 置 100ml量瓶中,
加流动相适量, 超声使溶解, 后定容至刻度, 摇匀, 滤过, 作为 供试品溶液, 量取 20μ1注入液相色 "i普仪, 记录色语图; 另取盐酸 多奈哌齐对照品适量, 制成浓度为 O. lmg/ml的对照品溶液, 同法 测定。 按外标法以峰面积计算出供试品中盐酸多奈哌齐的含量。 表 1 1 高温试验
表 12 高湿试验 实施例 盐酸多奈 崩解时限 溶出度 有关物质
时间 外观 哌齐含量
(s) ( % ) ( % )
( % )
0天 白色片 20.2 97.51 8.59 103.6 实施例 1 5天 白色片 18.3 100.07 10.15 103.95
10天 白色片 18.5 98.89 10.36 99.45
0天 白色片 21.3 98.75 9.23 102.7 实施例 2 5天 白色片 20.3 100.01 10.06 99.87
10天 白色片 19.2 100.05 9.87 98.23
0天 白色片 20.8 97.56 9.95 99.85 实施例 3 5天 白色片 18.2 99.84 10.05 103.01
10天 白色片 17.9 100.4 10.24 99.24
0天 白色片 25.23 93.23 15.20 97.86 比较例 2 5天 白色片 22.41 89.45 19.35 95.01
10天 白色片 22.08 88.56 18.78 93.21 表 13 光照试验 实施例 盐酸多奈 崩解时限 溶出度 有关物质
时间 外观 哌齐含量
(s) ( % ) ( % )
( % )
0天 白色片 20.2 97.51 8.59 103.6 实施例 1 5天 白色片 20.1 98.44 10.02 100.75
10天 白色片 20.5 100.06 11.13 97.9
0天 白色片 21.3 98.75 9.23 102.7 实施例 2 5天 白色片 20.3 98.25 10.58 98.76
10天 白色片 19.9 97.35 10.97 97.23
0天 白色片 20.8 97.56 9.95 99.85 实施例 3 5天 白色片 21.1 96.42 11.08 98.87
10天 白色片 21.9 95.97 11.34 96.42
0天 白色片 25.23 93.23 15.20 97.86 比较例 2 5天 白色片 23.1 90.44 17.21 93.24
10天 微黄色片 25.5 89.06 20.02 92.13
高温试验、 高湿试验和光照试验的结果表明, 与比较例相比, 本发明的产品外观良好, 崩解时间、 溶出度均优异, 盐酸多奈哌 齐的含量没有降低, 稳定性良好,。
已经根据优选实施例对本发明作了描述。 应当理解的是前面 的描述和实施例仅仅为了举例说明本发明而已。 在不偏离本发明 的精神和范围的前提下, 本领域技术人员可以设计出本发明的多 种替换方案和改进方案, 其均应被理解为在本发明的保护范围之 内。 产业实用性
盐酸多奈哌齐口腔崩解片采用粉末直接压片技术,将药物的粉 末与特定的崩解剂混合后直接压制成片。 本发明采用直接压片法 制备的盐酸多奈哌齐口腔崩解片与传统的片剂生产工艺湿法制粒 相比, 由于其制作过程不需制粒、 干燥, 所以节能省时, 生产成 本低, 另一方面, 具有产品质量稳定, 工业自动化程度高等优点。
Claims
1. 一种盐酸多奈哌齐口腔崩解片, 其包含盐酸多奈哌齐和崩 解剂, 其特征在于: 将盐酸多奈哌齐和崩解剂的混合物直接粉末 压片获得。
2. 根据权利要求 1 所述的盐酸多奈哌齐口腔崩解片, 其特征 在于: 还包含选自填充剂、 矫味剂、 粘合剂、 泡腾剂、 助流剂、 润滑剂或包衣材料中的至少一种, 以重量比计, 盐酸多奈哌齐 2—50% , 填充剂 10— 80% , 崩解剂 2— 35%, 矫味剂 1一 40% , 粘 合剂 0— 10%,泡腾剂 0— 30% ,助流剂 0.01— 5 %,润滑剂 0.3—3%, 包衣材料 0— 40%, 总量为 100 %。
3. 根据权利要求 1 所述的盐酸多奈哌齐口腔崩解片, 其特征 在于: 所述崩解剂选自交联聚乙烯吡咯烷酮、 羧甲基淀粉钠、 低 取代羟丙基纤维素、 交联羧曱基纤维素钠和大豆多糖中的一种或 多种。
4. 根据权利要求 3 所述的盐酸多奈哌齐口腔崩解片, 其特征 在于: 所述崩解剂是交联聚乙烯吡咯烷酮和低取代羟丙基纤维素 的混合物。
5. 根据权利要求 4 所述的盐酸多奈哌齐口腔崩解片, 其特征 在于获得的片剂的硬度在 10至 45牛顿, 崩解时间在 1 - 60秒。
6. 根据权利要求 2 所述的盐酸多奈哌齐口腔崩解片, 其特征 在于:
所述粘合剂选自淀粉、 预胶化淀粉、 糊精、 麦芽糖糊精、 蔗糖、 阿拉伯胶、 曱基纤维素、 羧曱基纤维素、 乙基纤维素、 聚乙烯醇、 聚乙二醇、 聚乙烯吡咯烷酮、 海藻酸及海藻酸盐、 黄原胶和羟丙 基曱基纤维素中的一种或多种,
所述填充剂选自甘露醇、 木糖醇、 山梨醇、 麦芽糖、 微晶纤维 素、 聚合糖、 葡萄糖、 乳糖、 蔗糖、 糊精和淀粉中的一种或多种, 所述矫味剂选自甘露醇、 木糖醇、 甜菊甙、 乳糖、 果糖、 蔗糖、 蛋白糖、 麦芽糖醇、 甘草甜素、 环己氨基磺酸钠、 明胶、 阿司帕 坦、 香蕉香精、 菠萝香精、 香兰素、 香橙香精、 桔子香精、 薄荷 香精、 人参香精、 草莓香精和柠檬酸中的一种或多种,
所述助流剂选自微粉硅胶、滑石粉和水合硅铝酸钠中的一种或 多种,
所述润滑剂选自硬脂酸镁、 硬脂酸钙、 硬脂酸锌、 单硬脂酸甘 油脂、 聚乙二醇、 氢化植物油、 硬脂富马酸钠、 聚氧乙烯单硬脂 酸酯、 单月桂蔗糖酸酯、 月桂醇硫酸钠、 月桂醇硫酸妹、 十二烷 基硫酸镁和滑石粉中的一种或多种,
所述包衣材料选自明胶、 阿拉伯胶、 海藻酸盐、 壳聚糖、 羧甲 基纤维素盐、 醋酸纤维素酞酸酯、 乙基纤维素、 曱基纤维素、 羟 丙甲纤维素、 丙烯酸树脂类、 聚乙烯醇、 聚乙烯吡咯烷酮和聚乙 二醇中的一种或多种。
7. 一种盐酸多奈哌齐口腔崩解片的制备方法, 其特征在于, 采用直接压片法, 包含以下步骤:
(1 ) 将崩解剂与盐酸多奈哌齐混合均勾, 任选地加入选自填充 剂、 粘合剂、 泡腾剂、 矫味剂、 助流剂包衣材料和润滑剂中的至 少一种并混合均勾, 得到混合物;
(2) 将上述 ( 1 ) 所得混合物送入压片机压片即得。
8. 根据权利要求 7所述的盐酸多奈哌齐口腔崩解片制备方法, 其特征在于: 对盐酸多奈哌齐进行掩味包衣, 用于掩味处理的包 衣材料选自明胶、 阿拉伯胶、 海藻酸盐、 壳聚糖、 羧曱基纤维素 盐、 醋酸纤维素酞酸酯、 乙基纤维素、 甲基纤维素、 羟丙曱纤维 素、 丙烯酸树脂类、 聚乙烯醇、 聚乙烯吡咯烷酮和聚乙二醇任意 一种或两种以上的混合物。
9. 根据权利要求 7所述的盐酸多奈哌齐口腔崩解片制备方法, 其中, 泡腾剂选自苹果酸或柠檬酸、 与碳酸氢钠或碳酸钠的混合 物。
10. 由权利要求 7所述的盐酸多奈哌齐口腔崩解片制备方法得 到的盐酸多奈哌齐口腔崩解片。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810225017A CN101756917A (zh) | 2008-10-24 | 2008-10-24 | 盐酸多奈哌齐口腔崩解片及其制备方法 |
CN200810225017.1 | 2008-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010045788A1 true WO2010045788A1 (zh) | 2010-04-29 |
Family
ID=42118914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/001179 WO2010045788A1 (zh) | 2008-10-24 | 2009-10-23 | 盐酸多奈哌齐口腔崩解片及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101756917A (zh) |
WO (1) | WO2010045788A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106491566A (zh) * | 2016-09-22 | 2017-03-15 | 北京万全德众医药生物技术有限公司 | 一种盐酸左西替利嗪口腔速溶膜及其制备方法 |
CN112587490A (zh) * | 2020-12-22 | 2021-04-02 | 宁波第二激素厂 | 一种烯丙孕素片剂及其制备方法 |
CN115887396A (zh) * | 2023-01-06 | 2023-04-04 | 北京中科利华医药研究院有限公司 | 一种醋甲唑胺口崩片及其制备方法和应用 |
CN116019773A (zh) * | 2021-10-27 | 2023-04-28 | 北京量子高科制药科技有限公司 | 一种苯磺酸氨氯地平冻干口腔崩解片及其制备方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012035409A1 (en) * | 2010-09-14 | 2012-03-22 | Rubicon Research Private Limited | Sustained release compositions of anti-alzheimer's agents |
CN102525970B (zh) * | 2010-12-31 | 2015-11-25 | 量子高科(北京)研究院有限公司 | 一种抗痴呆药物口腔崩解片及其制备方法 |
TW201318650A (zh) * | 2011-11-02 | 2013-05-16 | Hua Yu Wuxi Pharmaceutical Co Ltd | 口崩片組成物 |
CN106692085A (zh) * | 2016-11-24 | 2017-05-24 | 杭州新诺华医药有限公司 | 一种多奈哌齐口腔崩解片及其制备方法 |
CN106727371B (zh) * | 2016-12-08 | 2021-03-05 | 江苏豪森药业集团有限公司 | 盐酸多奈哌齐药物组合物及其制备方法 |
CN112315925A (zh) * | 2020-11-16 | 2021-02-05 | 仁和堂药业有限公司 | 盐酸米安色林片及其制备工艺 |
CN114748435B (zh) * | 2022-05-18 | 2023-06-23 | 四川升和药业股份有限公司 | 一种盐酸多奈哌齐口崩片及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1695617A (zh) * | 2004-05-13 | 2005-11-16 | 杭州民生药业集团有限公司 | 甲磺酸氨氯地平口腔崩解片及其制备方法 |
CN1795857A (zh) * | 2004-12-30 | 2006-07-05 | 北京德众万全医药科技有限公司 | 一种盐酸多奈哌齐的掩味组合物及含有该组合物的制剂 |
WO2006074951A2 (en) * | 2005-01-14 | 2006-07-20 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Orally disintegrating composition of olanzapine or donepezil |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2766089B1 (fr) * | 1997-07-21 | 2000-06-02 | Prographarm Lab | Comprime multiparticulaire perfectionne a delitement rapide |
-
2008
- 2008-10-24 CN CN200810225017A patent/CN101756917A/zh active Pending
-
2009
- 2009-10-23 WO PCT/CN2009/001179 patent/WO2010045788A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1695617A (zh) * | 2004-05-13 | 2005-11-16 | 杭州民生药业集团有限公司 | 甲磺酸氨氯地平口腔崩解片及其制备方法 |
CN1795857A (zh) * | 2004-12-30 | 2006-07-05 | 北京德众万全医药科技有限公司 | 一种盐酸多奈哌齐的掩味组合物及含有该组合物的制剂 |
WO2006074951A2 (en) * | 2005-01-14 | 2006-07-20 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Orally disintegrating composition of olanzapine or donepezil |
Non-Patent Citations (2)
Title |
---|
ZHANG YUANYUAN ET AL.: "The preparation of donepezil hydrochloride orally disintegrating HANG Yuanyuan et al. The preparation of donepezil hydrochloride orally disintegrating tablets and quality control.", CHINESE JOURNAL OF HOSPITAL PHARMACY., vol. 28, no. 23, December 2008 (2008-12-01), pages 2041 - 2043 * |
ZOU HUA .: "Extension and Application of Direct Compression Technology.", JOURNAL OF TAIZHOU POLYTECHNICAL INSTITUTE., vol. 8, no. 01, February 2008 (2008-02-01), pages 60 - 63 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106491566A (zh) * | 2016-09-22 | 2017-03-15 | 北京万全德众医药生物技术有限公司 | 一种盐酸左西替利嗪口腔速溶膜及其制备方法 |
CN112587490A (zh) * | 2020-12-22 | 2021-04-02 | 宁波第二激素厂 | 一种烯丙孕素片剂及其制备方法 |
CN112587490B (zh) * | 2020-12-22 | 2023-07-04 | 宁波第二激素厂 | 一种烯丙孕素片剂及其制备方法 |
CN116019773A (zh) * | 2021-10-27 | 2023-04-28 | 北京量子高科制药科技有限公司 | 一种苯磺酸氨氯地平冻干口腔崩解片及其制备方法 |
CN115887396A (zh) * | 2023-01-06 | 2023-04-04 | 北京中科利华医药研究院有限公司 | 一种醋甲唑胺口崩片及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101756917A (zh) | 2010-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010045788A1 (zh) | 盐酸多奈哌齐口腔崩解片及其制备方法 | |
EP2842549B1 (en) | Orally disintegrating tablet and method for producing same | |
TWI673051B (zh) | 恩雜魯它脈(enzalutamide)之調和物 | |
US6455053B1 (en) | Quickly soluble solid preparations | |
ES2347968T3 (es) | Preparacion solida que se disgrega rapidamente. | |
RU2648760C2 (ru) | Фармацевтическая композиция, содержащая оксигидроксид железа, способ ее получения и применение | |
EP2246052B1 (en) | Orally rapidly disintegrating tablet comprising imidafenacin | |
JP2023063386A (ja) | シロドシンの苦味をマスキングした経口投与製剤 | |
CA2599308A1 (en) | Rapidly disintegrating dosage form comprising magnesium carbonate heavy | |
JP2010270160A (ja) | 錠剤の製造方法 | |
JPWO2007074856A1 (ja) | 口腔内崩壊性固形製剤の製造法 | |
WO2011019043A1 (ja) | 2種以上の粒子を含有する口腔内速崩壊錠 | |
KR20150001720A (ko) | 1-(3-(2-(1-벤조티오펜-5-일)에톡시)프로필)아제티딘-3-올 또는 그 염을 함유하는 고형 의약 조성물 | |
JP2008285434A (ja) | 口腔内速崩壊錠 | |
CN101209249A (zh) | 间苯三酚口腔崩解片及其制备方法 | |
CN101461788A (zh) | 一种间苯三酚口腔崩解片及其制备方法 | |
KR101111534B1 (ko) | 구강 속붕해성 조성물 및 이의 제조방법 | |
CN112426408B (zh) | 一种褪黑素组合物及其制备工艺 | |
WO2006109737A1 (ja) | 苦味が低減されたプランルカスト水和物を含有する製剤 | |
KR101813065B1 (ko) | 알긴산 및/또는 알긴산염을 포함하는 고형 제제 | |
JP3899522B2 (ja) | 苦味が低減されたプランルカスト水和物を含有する製剤 | |
CN114129525B (zh) | 美克洛嗪口腔崩解片及其制备方法 | |
JP2008094751A (ja) | プランルカスト水和物含有医薬組成物 | |
TWI651085B (zh) | N-[5-[2-(3,5-二甲氧基苯基)乙基]-2h-吡唑-3-基]-4-[(3r,5s)-3,5-二甲基哌-1-基]苯甲醯胺之醫藥調配物 | |
KR101244627B1 (ko) | 올란자핀을 함유하는 확산정 조성물 및 이에 의해 형성된 정제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09821509 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09821509 Country of ref document: EP Kind code of ref document: A1 |